B. B. Blanco Cáceres

Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?

F. Blanco, J. Pego-Reigosa, C. Sánchez-Piedra, 2020, Rheumatology.

AB0822 VITAMIN D (25OHD) IN PATIENTS WITH CHRONIC RHEUMATIC DISEASESRECEIVING TREATMENT WITH ADALIMUMAB. DESCRIPTIVE STUDY OF A COHORT

M. Fernández, J. Lavilla, B. B. Blanco Cáceres, 2019, Abstracts Accepted for Publication.

Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology.

F. Blanco, A. Olivé, J. Pego-Reigosa, 2019, Reumatologia clinica.

SAT0441 SKIN ADVERSE EVENTS WITH FEBUXOSTAT IN GOUT PATIENTSWITH PREVIOUS SKIN REACTIONS TO ALLOPURINOL. A MULTICENTRE DESCRIPTIVE STUDY

E. Pascual, M. Andrés, F. Sivera, 2019, Saturday, 15 June 2019.

Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

C. Díaz-Torné, E. Pascual, M. Andrés, 2020, Annals of the Rheumatic Diseases.

AB1249 HOSPITAL ADMISSIONS IN PATIENTS WITH CHRONIC RHEUMATIC DISEASESRECEIVING ADALIMUMAB. DESCRIPTIVE STUDY OF A COHORT

B. B. Blanco Cáceres, F. Pérez-Ruiz, Paula García Escudero, 2019, Abstracts Accepted for Publication.

Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology.

Sagrario Bustabad, J. Pego-Reigosa, C. Sánchez-Piedra, 2017, Reumatologia clinica.